SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate long-term Week 40 clinical data for their flagship candidate, sonelokimab, which is set to be presented at an upcoming dermatology conference. The community is heavily focused on the drug's potential to establish a 'best-in-class' profile for treating Hidradenitis Suppurativa, with active discussions revolving around institutional accumulation patterns, recent analyst upgrades, and persistent speculation regarding potential M&A interest from major pharmaceutical players.

Borr Drilling Ltd. engages in the provision of offshore drilling services to the oil and gas industry. It operates through Dayrate; and Integrated Well Services (IWS) segments. The Dayrate segment consists of rig charters and ancillary services. The IWS segment provides integrated well services through Opex and Akal. The company was founded by Tor Olav Trøim on August 8, 2016 and is headquartered in Hamilton, Bermuda.

Borr Drilling Ltd

Borr Drilling is capturing market attention as investors weigh the impact of recent contract expansions and a transition in executive leadership against persistent debt concerns. The community remains divided, with many traders actively accumulating shares based on potential upside in the offshore rig market, while others express caution regarding the company's long-term financial leverage.

iShares Trust - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF (INDA) is currently in focus as investors weigh the potential impact of looming U.S. reciprocal tariffs and geopolitical tensions against the nation's robust long-term growth story and ongoing trade deal negotiations. While market participants are actively discussing the risks of foreign equity outflows and currency volatility, many community members remain bullish on India's resilience and its strategic potential as a global manufacturing hub.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as investors weigh persistent geopolitical uncertainty and fiscal policy concerns against the broader strength of U.S. markets. Community discourse remains heavily polarized, with many users debating the impact of ongoing administration conflicts on long-term portfolio stability and the relative merits of broad index-based strategies versus active trading.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently trending due to intense community frustration surrounding difficulties with token claims, confusing wallet connectivity, and widespread accusations that the project operates as a scam. While some proponents continue to push the mining app and long-term potential, many investors are actively sharing warnings and seeking legal recourse due to the lack of clear, functional access to their holdings.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is drawing significant investor attention due to the finalized acquisition of Arcadium Lithium and a strategic focus on expanding its U.S. copper footprint, highlighted by the fast-tracking of its Resolution Copper project. While the stock navigates iron ore price volatility and ongoing geopolitical trade concerns, the community remains bullish on its long-term commodity cycle prospects and its transition into critical battery minerals.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is currently a major focus for traders who are monitoring the development of its 11GW Project Matador campus, with significant community discourse revolving around the anticipated announcement of an anchor tenant. Investors are weighing high-conviction bullish cases involving institutional support and power infrastructure demands against concerns over stock volatility, ongoing class action headlines, and the need for definitive contract signings to validate the company's long-term valuation.

Honeywell International, Inc. is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It operates through the following business segments: Aerospace Technologies, Industrial Automation, Building Automation, Energy and Sustainability Solutions, and Corporate and All Other. The company was founded by Albert M. Butz in 1906 and is headquartered in Charlotte, NC.

Honeywell International Inc

Honeywell International is gaining investor attention as it progresses with its strategic plan to split into three independent entitiesAerospace, Automation, and Advanced Materials (Solstice)aiming to unlock shareholder value similar to past industrial conglomerates. The stock is currently oscillating amid broader industrial sector volatility, while community discussion remains focused on the potential upside of these spin-offs and the long-term growth prospects of its majority-owned quantum computing subsidiary, Quantinuum.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense debate among investors as they approach their upcoming earnings announcement, with many closely tracking the company's aggressive store expansion versus the risks posed by its high valuation in a competitive retail landscape. While some market participants express concern over potential share dilution and inflationary pressures on consumer spending, the community is actively buzzing over strong unit-level economics and the company's ability to maintain long-term growth momentum.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing attention as community members debate its long-term potential as a foundational web3 data infrastructure play amidst recent technical upgrades like Substreams and integration with Anthropic's Model Context Protocol. While some investors view current price levels as an undervalued accumulation opportunity for the next market cycle, others remain skeptical, pointing to historical supply dilution and persistent sideways price action as ongoing concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase - Here's What Happened...

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's What Happened...

Research Analysts Issue Forecasts for FDMT FY2030 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will earn...

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised shares of 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday...

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade...

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada raised their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday...

Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Chardan Capital restated a "buy" rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday...

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$9.33
Prev Close	$10.18
Open	$10.00
Dividend Yield	0.00%
50-Day Moving Average	$8.89
Beta	1.28
Avg. Volume	741,778.95
PE Ratio	-3.71

52-Week High	$12.34
52-Week Low	$2.24
Market Capitalization	$476.31M
EPS (Annual)	-$2.42
Price to Book	1.06
Revenue Per Employee	$434,739.80

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FDMT News

FDMT4D Molecular Therapeutics Inc